On May 21, 2024, the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) published a warning letter issued to Akan Biosciences, Inc.
Center for Biologics Evaluation and Research and Food and Drug Administration FDA publish warning letter to Akan Biosciences for unresolved inspection observation
On May 22, 2023, the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) issued an untitled letter to AT Venture Center for Global.
Center for Biologics Evaluation and Research is on a roll in enforcing HCT/P regulations, this enforcement trend indicates that FDA is keeping a close eye on the promotion of such products and making sure they are properly classified and undergo appropriate premarket review.
On March 1, 2023, the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) published its first untitled letter of the year to Thomas Advanced Medical LLC (Thomas).